Neurocrine Biosciences, Inc. today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the ...
Argus Research analyst Jasper Hellweg maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares ...
As generative AI continues to reshape the legal and corporate landscapes, actionable steps should now be at the forefront of crisis communication plans to help firms combat the rapid spread of ...
8h
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...
Patent law specialist Hoffmann Eitle is taking over the Dusseldorf office of boutique KSVR (König - Szynka - Tilmann - von Renesse) next month. KSVR partners Gregor König, Dorothea von Renesse and ...
We recently published a list of Jim Cramer Discussed These 18 Stocks As Inflation Dropped. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback